Tipharco seeks new board members, including independent director

Tipharco Pharmaceutical Joint Stock Company (DTG) has announced an extraordinary information disclosure regarding the nomination and candidacy for additional members of its board of directors for the 2021-2025 term. The board of directors issued Resolution No. 34/2025/NQ-HĐQT-DTG on December 12, 2025, approving the documents for shareholders to exercise their nomination and election rights.

The company plans to elect two additional board members, including one independent member, to serve the remaining duration of the 2021-2025 term. Shareholders holding common shares can combine their voting rights to nominate candidates. For instance, shareholders holding 5% to less than 10% of total voting shares can nominate one candidate, while those holding 80% to less than 90% can nominate up to eight.

Nomination and candidacy documents, including a self-declared resume and notarized copies of identification and qualifications, must be submitted to Tipharco Pharmaceutical JSC by 4:30 p.m. on December 17, 2025. The full set of documents and regulations are available on the company's website. The selection process will adhere to a cumulative voting method.